BNP Paribas Financial Markets Has $1.81 Million Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

BNP Paribas Financial Markets grew its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 1,732.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 849,658 shares of the company's stock after purchasing an additional 803,284 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.41% of Allogene Therapeutics worth $1,810,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ALLO. Lynx1 Capital Management LP raised its position in shares of Allogene Therapeutics by 75.3% in the fourth quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company's stock valued at $23,163,000 after purchasing an additional 4,672,349 shares during the period. Foresite Capital Management VI LLC bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at approximately $7,345,000. Gilead Sciences Inc. bought a new position in shares of Allogene Therapeutics in the fourth quarter valued at approximately $2,464,000. Dimensional Fund Advisors LP raised its position in shares of Allogene Therapeutics by 30.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company's stock valued at $7,586,000 after purchasing an additional 831,146 shares during the period. Finally, Barclays PLC raised its position in shares of Allogene Therapeutics by 122.0% in the fourth quarter. Barclays PLC now owns 761,286 shares of the company's stock valued at $1,621,000 after purchasing an additional 418,313 shares during the period. Institutional investors own 83.63% of the company's stock.

Insiders Place Their Bets

In other Allogene Therapeutics news, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction on Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the sale, the chief executive officer now owns 5,276,569 shares in the company, valued at $10,342,075.24. The trade was a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 61,757 shares of company stock worth $115,873 over the last 90 days. Corporate insiders own 13.20% of the company's stock.

Allogene Therapeutics Stock Down 2.8%

ALLO traded down $0.03 during trading on Friday, reaching $1.06. 2,853,612 shares of the company's stock were exchanged, compared to its average volume of 3,333,691. Allogene Therapeutics, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $3.78. The business has a 50 day moving average price of $1.41 and a 200 day moving average price of $1.86. The company has a market capitalization of $231.85 million, a P/E ratio of -0.68 and a beta of 0.60.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.28). As a group, research analysts forecast that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ALLO shares. Oppenheimer dropped their price target on shares of Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 14th. Truist Financial dropped their target price on shares of Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Piper Sandler dropped their target price on shares of Allogene Therapeutics from $9.00 to $7.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $14.00 target price on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Robert W. Baird dropped their target price on shares of Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $8.44.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).